Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Symbioflor 1
- Development stage
- Unknown
- Lead developer
- Symbiopharm
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Symbioflor 1 is a licensed probiotic medicinal product containing live *Enterococcus faecalis* bacteria (specifically strain DSM 16440). Developed by SymbioPharm (part of the Symbio Herborn Group), it is primarily indicated for the treatment of recurrent respiratory infections, including chronic sinusitis and bronchitis. The drug functions as an immunomodulator; the live bacteria interact with the gut-associated lymphoid tissue (GALT), which in turn stimulates the systemic immune response and enhances mucosal immunity in the respiratory tract. It is typically administered as oral drops and is recognized as a medicinal product in Germany rather than a simple dietary supplement.
- Brand names
- Symbioflor 1Symbioflor1Symbioflor-1
- Other names
- Enterococcus faecalis DSM 16440
Beyond the preview
Go deeper on Symbioflor 1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Symbioflor 1.